Adelaide researchers have identified a promising new biomarker and treatment target for ovarian cancer that could markedly ...
The U.S. Food and Drug Administration (FDA) has granted fast track designation to the antibody-drug conjugate JSKN003 for the ...
Adelaide researchers have identified a promising new biomarker and treatment target for ovarian cancer that could markedly ...
Cancer immunotherapy, which uses drugs that stimulate the body's immune cells to attack tumors, is a promising approach to ...
Nanoparticles carrying IL-12 are non-toxic, elicit strong systemic antitumor immunity, and sensitize ovarian tumors to ICI therapy, a new study shows.
The annual event will be held Saturday, Nov. 8 from 8 a.m. - 12 p.m. at Cranes Roost Park in Altamonte Springs.
Scientists found that nearly every cancer harbors its own distinct community of microbes – tiny passengers that can influence ...
Scientists in Australia have identified a promising new biomarker and treatment target for ovarian cancer that could markedly improve the outlook for women diagnosed with this aggressive disease.
The FDA has granted fast track designation to JSKN003, a biparatopic HER2-targeting antibody-drug conjugate (ADC), for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback